Results 31 to 40 of about 112,243 (300)
The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. [PDF]
, 2010 Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis and asthma.
Alex Berndt +16 more
core +2 more sources
Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase [PDF]
Trends in Pharmacological Sciences, 2013 Phosphoinositide (PI) 3-kinases are essential regulators of cellular proliferation, survival, metabolism, and motility that are frequently dysregulated in human disease. The design of inhibitors to target the PI 3-kinase/mTOR pathway is a major area of investigation by both academic laboratories and the pharmaceutical industry.
Hashem A, Dbouk, Jonathan M, Backer
openaire +2 more sources
Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]
, 2018 The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk +2 more
core +2 more sources
Antithrombotic phosphoinositide 3‐kinase β inhibitors in humans: a ‘shear’ delight! [PDF]
Journal of Thrombosis and Haemostasis, 2012 Jackson SP, Schoenwaelder SM. Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a ‘shear’ delight!J Thromb Haemost 2012; 10: 2123–6.See also Nylander S, Kull B, Bjorkman JA, Ulvinge J-C, Oakes N, Emanuelsson BM, Andersson M, Skarby T, Inghardt T, Fjellstrom O, Gustafsson D.
S P, Jackson, S M, Schoenwaelder
openaire +2 more sources
The multifaceted roles of PI3Kγ in hypertension, vascular biology, and inflammation [PDF]
, 2016 PI3Kγ is a multifaceted protein, crucially involved in cardiovascular and immune systems. Several studies described the biological and physiological functions of this enzyme in the regulation of cardiovascular system, while others stressed its role in ...
Carnevale, Daniela +2 more
core +2 more sources
Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling [PDF]
International Journal of Molecular Sciences, 2020 Signaling pathways regulated by the phosphoinositide 3-kinase (PI3K) enzymes have a well-established role in cancer development and progression. Over the past 30 years, the therapeutic potential of targeting this pathway has been well recognized, and this has led to the development of a multitude of drugs, some of which have progressed into clinical ...
Tania Maffucci, Marco Falasca
openaire +3 more sources
CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
Zhongliu Fangzhi Yanjiu, 2019 Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR ...
ZHANG Baihong, YUE Hongyun
doaj +1 more source
Role of mTOR signaling in tumor microenvironment. An overview [PDF]
, 2018 The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara +8 more
core +2 more sources
Tumor Biology, 2017 In this study, we investigated the underlying mechanism of the phosphoinositide 3-kinase/Akt– and Wnt/β-catenin-mediated promotion of epithelial-to-mesenchymal transition by epigenetic regulation of histone acetylation in gastric cancer.
Yue Song +5 more
doaj +1 more source
The Treatment of Activated PI3Kδ Syndrome
Frontiers in Immunology, 2018 Activated phosphoinositide 3-kinase δ syndrome (APDS), also known as PASLI disease (p110d-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency) are combined immunodeficiencies resulting from gain-of-function mutations in ...
Tanya I. Coulter, Andrew J. Cant
doaj +1 more source